reptides › libido › gonadorelin

gonadorelin

synthetic GnRH. historical human use, current US labels are animal-drug products, and TRT-clinic use is its own off-label lane.

tier C · libido · FDA '82 Factrel · diag

verdict

synthetic GnRH. historical Lutrepulse approval, current US labels are animal-drug products, and TRT-clinic use is a separate off-label lane.

if you're asking about gonadorelin as an HCG alternative for TRT — the theoretical appeal is real: act upstream at the pituitary to preserve the full HPG axis. the pharmacokinetics work against it. plasma half-life is 2-4 minutes, and occasional subcutaneous injection cannot mimic the physiological 90-minute pulse pattern. clinicians who compare the two generally report HCG produces cleaner outcomes.

if you're asking why TRT clinics reach for it at all — HCG access friction. the BPCIA 2020 reclassification of HCG as a biologic shut down the compounding pathway in the US. gonadorelin is cheap on the research-chemical market and available when HCG isn't. that's the practical lane, not pharmacological superiority. FDA's April 22, 2026 503A categories document does not place gonadorelin acetate in category 1. prior Lutrepulse approval should not be treated as current bulks-list clearance.

if you came in via the diagnostic / fertility pulsatile-pump indication — this is what the molecule was actually approved for. pulsatile gonadorelin pump for ovulation induction in hypothalamic amenorrhea. the dosing is paced to mimic physiological pulses through an indwelling pump. that's a different protocol from anything available through clinic or vendor channels today.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why C-tier

C-tier because the compound is legitimately approved and works as designed for specific narrow indications (diagnostic testing, pulsatile pump-delivered ovulation induction), but the use case that drives grey-market demand (TRT testicular preservation) is off-label and faces real pharmacokinetic obstacles versus HCG, which is the usual tool for that job. The drug is real. The community indication is thin. Not B-tier because the TRT use case, which is what most people are buying it for, is not the compound's strength. Not D-tier because it's an actual approved drug and the biology works. The problem is tool-for-the-job, not compound quality.

the core tension

Gonadorelin is synthetic gonadotropin-releasing hormone with a real human clinical history, but the current US label landscape is not the TRT-clinic story. The TRT-community use case, gonadorelin as an alternative to HCG for preserving testicular function during testosterone therapy, is off-label, and the peptide's very short half-life (2-4 minutes) creates practical problems HCG doesn't have. The compound works, but it's being asked to do a job that another compound does better. The historical clinical use is legitimate. The off-label use that most grey-market buyers are pursuing is the weaker evidence case.

what it is

gonadorelin is synthetic gonadotropin-releasing hormone, a 10-amino-acid decapeptide identical to the endogenous hypothalamic hormone that controls the entire reproductive axis. the structure was determined by schally and guillemin in the early 1970s, work that won the 1977 nobel prize. older human products such as Factrel and Lutrepulse built the clinical pedigree; current U.S. Factrel labeling is animal-drug labeling, not a human TRT product.

what it does

binds the gnrh receptor in the anterior pituitary, triggering lh and fsh release, which drive testicular or ovarian steroidogenesis. it is the top of the hpg axis. every testosterone and estrogen signal downstream starts here. plasma half-life of 2 to 4 minutes was the practical limitation that drove pulsatile-pump delivery in the original ovulation-induction protocol.

origin

developed for diagnostic pituitary testing and pulsatile ovulation induction in primary hypothalamic amenorrhea. those human-use products are commercially gone in the U.S.; the visible current Factrel label is veterinary. Canada re-approved a subcutaneous Lutrepulse formulation in 2012, and U.S. TRT clinics still use compounded gonadorelin off-label.

why researchers are interested

trt clinics reach for it as an hcg alternative during hcg supply disruptions. theoretical appeal is real: act upstream at the pituitary, preserve the full axis rather than only the testicular receptor. it is also cheap on the research-chemical market versus hcg's recurring availability problems.

does it work

for the old diagnostic and pulsatile-fertility indications, yes, gonadorelin works as designed. for the trt-community use case, occasional subcutaneous injection to preserve testicular function, the pharmacokinetics fight you. a 2-to-4-minute half-life cannot mimic the physiological 90-minute pulse pattern with that schedule. clinicians who compare side by side generally find hcg produces cleaner outcomes. the drug works. it is just the wrong tool for the job most people buy it for. Regulatory side matters too: gonadorelin has historical approved-drug pedigree, but FDA's April 22, 2026 503A categories document does not place gonadorelin acetate in category 1. Prior Lutrepulse approval should not be treated as current bulks-list clearance. The recurring HCG access friction that drives gonadorelin demand is structural: the BPCIA 2020 reclassification of HCG as a biologic shut down the compounding pathway for HCG in the US.

claims vs the data

  • stimulates pituitary LH and FSH release — supported — Core established pharmacology. Gonadorelin is endogenous GnRH, this is what the molecule is for.
  • approved for inducing ovulation in anovulatory infertility — supported — Historical FDA approval as Lutrepulse. Pulsatile delivery via infusion pump. Real indication with real clinical trial base.
  • approved as pituitary diagnostic test — supported — FDA approved as Factrel for evaluating pituitary gonadotroph function, assess LH/FSH response to GnRH challenge. Real clinical diagnostic use.
  • preserves testicular function during TRT — partially true — Mechanism is plausible, stimulating endogenous LH/FSH should preserve testicular function. In practice, short half-life makes typical every-other-day injection schedules poorly suited to mimic physiological pulsatile GnRH release. Most TRT clinicians who compare gonadorelin to HCG find HCG produces better testicular preservation outcomes.
  • superior to HCG for TRT support — contradicted — Community claim sometimes promoted. The pharmacokinetic profile of gonadorelin (2-4 min half-life) vs HCG (~30 hour half-life) favors HCG for the TRT-support use case in practice. Some clinicians prefer gonadorelin for theoretical reasons (acts upstream, less direct testicular stimulation), but empirically HCG usually produces cleaner outcomes.
  • prevents fertility loss during TRT — weak — Theoretical basis exists. Clinical evidence specifically comparing fertility preservation between HCG and gonadorelin in TRT patients is limited. Neither is guaranteed to preserve fertility in all users; HCG has more real-world track record.

key facts

  • molecular formula: C55H75N17O13
  • molecular weight: 1182.3 Da
  • amino acids: 10
  • half-life: extremely short, 2-4 minutes in plasma. The primary practical limitation of the compound. Clinical use for ovulation induction historically required pulsatile IV delivery via pump.
  • type: decapeptide (synthetic gonadotropin-releasing hormone)
  • CAS: 33515-09-2
  • 1980s historical FDA approval era
  • 2-4 min plasma half-life
  • 1977 Nobel Prize for GnRH structure (Schally, Guillemin)
  • off-label status of TRT-community use case

frequently asked questions

What is gonadorelin?

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), a 10-amino-acid peptide identical to the natural hypothalamic hormone that regulates pituitary LH and FSH release. It has a real historical human diagnostic and fertility-use pedigree, but current US Factrel labeling is veterinary, not a human TRT product.

What does gonadorelin do?

Gonadorelin binds the GnRH receptor in the pituitary, triggering LH and FSH release which in turn stimulates testicular testosterone production in men or ovarian estrogen production in women. Its short half-life (2-4 minutes) produces a pulsatile stimulation pattern rather than the sustained suppression seen with longer-acting GnRH agonists.

How is gonadorelin typically administered?

Historical clinical diagnostic use used controlled bolus administration, while pulsatile fertility use required pump-style delivery. TRT-clinic use is off-label and does not have a registered trial dosing framework.

What are the side effects of gonadorelin?

Well-tolerated at clinical diagnostic doses. Community use at higher frequencies may cause injection-site reactions, transient headache, and fluctuations in mood reflecting hormonal changes. Long-term use with excessive frequency could theoretically cause pituitary desensitization.

Is gonadorelin FDA approved?

The human-use story is historical: older Factrel and Lutrepulse uses are no longer active US human products. Current Factrel labeling in the US is for cattle. Gonadorelin is not FDA-approved for TRT support or recreational use.

How much does gonadorelin cost?

Compounded gonadorelin from hormone clinics for TRT support is sold as a monthly package. On the research-chemical market it is cheaper than the clinic route.

related peptides

  • hcg — primary TRT-support peptide, typically clinically superior for that specific use case
  • triptorelin — longer-acting GnRH analog with different clinical positioning
  • kisspeptin-10 — upstream HPG axis peptide with related mechanism

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.